RhumbLine Advisers

RhumbLine Advisers’s Enliven Therapeutics ELVN Stock Holding History

RhumbLine Advisers’s Portfolio ELVN Stock Details ELVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.97M	Sell	50,188 -321	-0.6%	-$8.89K	﹤0.01%	1868
2025 Q4	$778K	Sell	50,509 -9,651	-16%	-$192K	﹤0.01%	2370
2025 Q3	$1.23M	Buy	60,160 +9,880	+20%	+$199K	﹤0.01%	2135
2025 Q2	$1.01M	Sell	50,280 -2,222	-4%	-$42.1K	﹤0.01%	2244
2025 Q1	$1.03M	Buy	52,502 +2,466	+5%	+$53.1K	﹤0.01%	2156
2024 Q4	$1.13M	Buy	50,036 +170	+0.3%	+$4.41K	﹤0.01%	2192
2024 Q3	$1.27M	Buy	49,866 +239	+0.5%	+$5.54K	﹤0.01%	2137
2024 Q2	$1.16M	Buy	49,627 +11,420	+30%	+$240K	﹤0.01%	2162
2024 Q1	$672K	Buy	38,207 +864	+2%	+$13.3K	﹤0.01%	2481
2023 Q4	$517K	Buy	37,343 +2,980	+9%	+$36.5K	﹤0.01%	2641
2023 Q3	$469K	Sell	34,363 -433	-1%	-$7.29K	﹤0.01%	2648
2023 Q2	$710K	Buy	+34,796	New	+$703K	﹤0.01%	2477

Other funds holding ELVN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Citadel Advisors

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return